title: Paraoxonase lactonase activity (PON-HTLase), asymmetric dimethylarginine (ADMA) and platelet activating factor-acetylhydrolase (PAF-AH) activity in non-obese women with PCOS.
abstract: OBJECTIVE
  Paraoxonase1 (PON1), exhibits both esterase activity (PON1-AREase) and homocysteine thiolactonase activity (PON1-HTLase) which respectively prevent LDL oxidation and detoxify homocysteine thiolactone (HTL). Platelet-activating factor-acetylhydrolase (PAF-AH) is an antioxidant enzyme preventing LDL oxidation by hydrolysis of oxidized phospholipids. Both of these enzymes exhibit a proatherogenic role. ADMA is an endogenous inhibitor of nitric oxide (NO) synthesis causing endothelial dysfunction. The aim was to compare non-obese PCOS patients with a BMI matched control group using the following characteristics: serum PON1-HTLase, ADMA, PAF-AH, and lipid and hormonal parameters.
  
  
  RESULTS
  77 women with PCOS and 25 healthy subject were recruited for this study, The controls were non-obese BMI and age matched with the patients. There were no significant differences with respect to age, BMI, FSH, free testosterone, DHEA, androstenadion, total cholesterol, triglycerides, HDL, LDL, VLDL, fasting glucose/insulin ratio and HOMA-IR among the groups (p > 0.05). However, total testosterone and fasting glucose levels were significantly higher in the PCOS group (p < 0.05). On the other hand, PON1-HTLase levels (39.6 ± 5.77 vs. 33.8 ± 8.2, p = 0.02) were significantly lower in the PCOS group while ADMA levels (1.14 ± 0.6 vs. 3.37 ± 6.4, p = 0.004) were significantly higher in the PCOS group. However, there was no significant difference in PAF-AH activity among the groups.
  
  
  CONCLUSIONS
  Decreased PON1-HTLase and increased ADMA levels might be a relevant marker for the development of future atherosclerotic heart disease (AHD) in non-obese PCOS patients. Further studies are needed to confirm our results.
authors.affiliation: Department of Biochemistry, Hacettepe University Kastamonu School of Medicine, Ankara, Turkey.
authors.forename: Tulin
authors.initials: T
authors.lastname: Bayrak
authors.forename: Polat
authors.initials: P
authors.lastname: Dursun
authors.forename: Ahmet
authors.initials: A
authors.lastname: Bayrak
authors.forename: Murat
authors.initials: M
authors.lastname: Gültekin
authors.forename: Ali
authors.initials: A
authors.lastname: Kolusarı
authors.forename: Erdinç
authors.initials: E
authors.lastname: Cakır
authors.forename: Merve
authors.initials: M
authors.lastname: Ozyurt
authors.forename: Hulusi B
authors.initials: HB
authors.lastname: Zeyneloğlu
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood*; D000293:Adolescent; D000328:Adult; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D043303:Aryldialkylphosphatase / Q000097:blood*; D015992:Body Mass Index; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D009765:Obesity; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000201:enzymology*; D055815:Young Adult
chemical_list: C018524:N,N-dimethylarginine; D001120:Arginine; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human